EyePoint, Inc. (EYPT) Form 8-K — Oct 19, 2026
EyePoint's Phase 3 LUCIA trial of DURAVYU in wet AMD missed its primary non-inferiority endpoint versus aflibercept, despite meeting secondary endpoints on treatment burden, anatomy and safety. The Board approved a strategic prioritization: concluding the wet AMD Phase 3 trials early and cutting approximately 53% of the workforce, with expected charges of about $9 million and estimated annualized savings of roughly $30 million. The company is now refocusing on DURAVYU in diabetic macular edema, with pivotal Phase 3 COMO and CAPRI topline data (551 patients) expected in Q4 2027.
Key figures
- Cash Position
- 118000000
- Dme readout
- Q4 2027
- Dme phase3 patients
- 551
- Annualized savings est
- $30 million
- Verona supplement free
- >70% of patients supplement-free for six months
- Restructuring charges est
- $9 million
- Workforce reduction percent
- 53
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.